Opus Genetics, Inc. Other than Temporary Impairment Losses, Investments
Opus Genetics, Inc. (IRD) reported Other than Temporary Impairment Losses, Investments of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2023-11-13
- Opus Genetics, Inc. other than temporary impairment losses, investments for the quarter ending 2023-09-30 was $0.00.
- Opus Genetics, Inc. other than temporary impairment losses, investments for the quarter ending 2023-06-30 was $0.00.
- Opus Genetics, Inc. other than temporary impairment losses, investments for the quarter ending 2023-03-31 was $0.00.
- Opus Genetics, Inc. other than temporary impairment losses, investments for the quarter ending 2022-12-31 was $0.00.
- Opus Genetics, Inc. other than temporary impairment losses, investments for fiscal 2022 was $0.00.
- Opus Genetics, Inc. other than temporary impairment losses, investments for fiscal 2021 was $0.00.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-08-11 | $0.00 derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | $0.00 derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $0.00 derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-08-12 | $0.00 derived: sum of 4 quarters · filed 2022-08-12 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-05-13 | $0.00 derived: sum of 3 quarters · filed 2022-05-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $0.00 derived: sum of 2 quarters · filed 2022-03-24 | $0.00 10-K · filed 2022-03-24 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |